Researchers report on a study investigating effects of ADT on prostate cancer health-related quality of life, sexual function, sexual bother, and mood for patients with prostate cancer and their partners.
[Breast Cancer: Targets and Therapy] Researchers present a review of the LHRH agonist triptorelin and the use of this agent to induce chemical castration in estrogen-sensitive breast cancer tumors in younger women.
In this study, researchers determined the efficacy of calcitriol, weight-bearing exercise, both, or daily multivitamins on bone formation and resorption in breast cancer survivors actively maintained on hormone therapy.
Women should be encouraged to optimize lifestyle and should not generally be treated with hormone therapy following breast cancer.
The risk of cardiovascular disease such as heart failure, arrhythmias, and conduction disorders are greater in men with localized prostate cancer who were treated with androgen deprivation therapy.
Osteoporosis medications were found to reduce bone mineral density loss and risk of fracture in men with nonmetastatic prostate cancer being treated with androgen-deprivation therapy.
How the body metabolizes next-generation anti-androgen agents affects their anti-tumor activity in the treatment of prostate cancer.
Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.
Male breast cancer patients are less likely than their female counterparts to receive adjuvant hormone therapy and postlumpectomy radiation.
New paradigm of hormone therapy, surgery, and radiation therapy was shown effective at achieving undetectable disease in patients with metastatic prostate cancer.
Abiraterone acetate and prednisone reduced PSA levels in a small group of clinical trial participants with metastatic prostate cancer who did not initially respond to ADT.
Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.
This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.
Nonadherence to Noncancer Medication Schedules Predicts Adherence to Adjuvant Hormone Therapy for Breast CancerJune 28, 2016
Patients who do not adhere to their medication schedules for chronic conditions prior to a breast cancer diagnosis were twice as likely to skip oral adjuvant hormonal therapy.
Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.
Researchers identified a cancer-causing gene triggered by alcohol use, providing a link between alcohol and breast cancer in cell-based research.
Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate CancerJanuary 07, 2016
Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.
Data collected from Japanese and Korean participants in the global PALOMA3 trial provide evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with advanced HR+/HER2- breast cancer.
Docetaxel should be added at initiation of standard of care treatment in men with prostate cancer; however, no evidence of survival improvement was seen with zoledronic acid therefore it is not recommended as part of standard of care for this patient population.
Adding continuous progestin to estrogen lowers the risk of endometrial cancer in postmenopausal women, according to a new study.
In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.
Gene Expression Test Can Lead to More Effective Treatment Decisions In Patients With Invasive Lobular Carcinoma (ILC) Breast CancerNovember 06, 2015
Most patients with invasive lobular carcinoma (ILC) breast cancer could be treated with hormones alone and not with chemotherapy.
Overall survival in men with rising PSA levels after prostatectomy for prostate cancer was statistically improved by adding a 24-month course of AAT during and after salvage radiotherapy, compared with salvage radiotherapy alone.
Researchers discovered a new explanation for why women with ER+ breast cancer develop resistance to hormone treatment, and a potential new approach that may overcome the problem.
In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.
Women with luminal A subtype breast cancer, especially those older than 60 years, may not need radiation treatment if they are already taking hormone therapy.
Researchers are examining what factors might make patients with prostate cancer more likely to experience hot flashes during and after therapy.
Men with prostate cancer that has spread to nearby lymph nodes may find the addition of radiation therapy to treatments that block the effects of testosterone beneficial.
Breast cancer patients given the hormone-blocking drug goserelin during chemotherapy experience less ovarian failure and are more likely to have successful pregnancies, according to study results.
The addition of radiation treatment to hormone therapy reduced more cancer deaths among older men locally advanced prostate cancer, compared to hormone therapy alone.
Sign Up for Free e-newsletters
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Clinical Research Nursing Staff an Important Part of Oncology Clinical Trial Programs
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Multimodal Follow-up Improved Postradiotherapy Sexual Health in Lower GI, Gynecologic Cancers
- Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Hair Dyes and Cancer Risk (Fact Sheet)
- Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning
- Counseling Intervention That Improved CHD is Applied to Cancer Risk in Men
- Low-fat Diet May Improve Overall Survival in Newly Diagnosed Breast Cancer
- Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer
- IDDS and SCS: Exploring Multimodal Approaches for Managing Cancer Pain
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|